Skip to content

Study on Functional Validation and Diagnostic Value of Novel Biomarkers ANXA3/SOCS3 for Acute Myocardial Infarction Based on Sphingolipid Metabolism

Study on Functional Validation and Diagnostic Value of Novel Biomarkers ANXA3/SOCS3 for Acute Myocardial Infarction Based on Sphingolipid Metabolism

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2600128224
Enrollment
Unknown
Registered
2026-07-16
Start date
2026-07-20
Completion date
Unknown
Last updated
2026-07-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Specific disease or symptomsAcute myocardial infarction (AMI) is myocardial necrosis caused by acute coronary occlusion. Main manifestations: ? Typical chest pain (retrosternal crushing pain radiating to left shoulder/arm, not relieved by nitroglycerin)

Interventions

Gold Standard:Fourth Universal Definition of Myocardial Infarction (2018): cardiac troponin elevation (>99th URL) with dynamic changes plus at least one evidence of myocardial ischemia (symptoms, ECG
Index test:Measurement of ANXA3 and SOCS3 mRNA expression levels: peripheral venous blood (5 mL) is collected, total RNA is extracted, and real-time quantitative polymerase chain reaction (RT-qPCR) is

Sponsors

The First Hospital Of Jiaxing
Lead Sponsor

Eligibility

Sex/Gender
All
Age
35 Years to 75 Years

Inclusion criteria

Inclusion criteria: 1.Meet the World Health Organization (WHO) 2008 revised diagnostic criteria for AMI (cardiac troponin >99th percentile of URL with dynamic changes, or new pathological Q waves, ST-segment elevation/depression, T-wave inversion on ECG); 2.Time from symptom onset to hospital admission <=72 hours; 3.Aged 35 to 75 years (inclusive); 4.Willing to participate and provide written informed consent.

Exclusion criteria

Exclusion criteria: 1. Severe Liver Or Kidney Dysfunction: ALT/AST > 3× ULN, Or Serum Creatinine > 177 µmol/L, Or eGFR 38.5?, White Blood Cell Count > 12×10^9/L Or 50 mg/L, Active Tuberculosis, Viral Hepatitis (Positive HBV DNA Or HCV RNA), HIV Infection. 5. Recent Surgery Or Trauma: Major Surgery (Thoracotomy, Laparotomy, Craniotomy, Joint Replacement, Etc.) Or Severe Trauma (Multiple Fractures, Internal Organ Injury) Within The Past 3 Months. 6. Pregnancy Or Lactation: Positive Pregnancy Test (For Women Of Childbearing Potential) Or Currently Breastfeeding. 7. Psychiatric Disorders Or Cognitive Impairment: Schizophrenia, Bipolar Disorder, Major Depressive Disorder, Dementia, Alzheimer's Disease, Etc., That Preclude Understanding Of The Study Or Completion Of Follow-Up. 8. History Of Substance Or Alcohol Abuse: Documented Drug Dependence Or Alcohol Abuse (Average Daily Alcohol Intake > 40 g For Males Or > 20 g For Females) Within The Past Year. 9. Incomplete Clinical Data Or Refusal To Provide Blood Sample: Missing Key Clinical Information (Symptom Onset Time, ECG, Cardiac Enzyme Profiles) In Medical Records, Or Refusal To Provide An Extra Blood Sample For Study Purposes. 10. Concurrent Participation In Other Interventional Clinical Trials: Participation In Any Other Drug, Device, Or Biologic Interventional Trial Within The Past 3 Months (Observational Studies Are Allowed).

Design outcomes

Primary

MeasureTime frame
mRNA expression levels of ANXA3 and SOCS3, and their combined diagnostic performance (AUC, sensitivity, specificity).;Accuracy;

Countries

China

Contacts

Public ContactHaihua Pan

The First Hospital Of Jiaxing

18767232909@qq.com+86 573 82519988

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Sep 11, 2026